Results 11 to 20 of about 24,664,088 (323)

Causal Effect of Plasminogen Activator Inhibitor Type 1 on Coronary Heart Disease [PDF]

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2017
BackgroundPlasminogen activator inhibitor type 1 (PAI‐1) plays an essential role in the fibrinolysis system and thrombosis. Population studies have reported that blood PAI‐1 levels are associated with increased risk of coronary heart disease (CHD ...
Ci Song, Stephen Burgess, John D. Eicher, Christopher J. O'Donnell, Andrew D. Johnson   +4 more
doaj   +3 more sources

Inhibiting ERK Activation with CI-1040 Leads to Compensatory Upregulation of Alternate MAPKs and Plasminogen Activator Inhibitor-1 following Subtotal Nephrectomy with No Impact on Kidney Fibrosis [PDF]

, 2015
Extracellular-signal regulated kinase (ERK) activation by MEK plays a key role in many of the cellular processes that underlie progressive kidney fibrosis including cell proliferation, apoptosis and transforming growth factor β1-mediated epithelial to ...
AA Eddy, Arif Khwaja, B Conway, B Hinz, C Stambe, D Bokemeyer, D Bokemeyer, D Feliers, David Long, DY Rhyu, E Diaz-Flores, Faith Hannah Nutter, FY Ma, FY Ma, FY Ma, G Wolf, GA Reif, GM D'Abaco, H Fujita, H Ha, H Tamouza, HJ Anders, J Chen, John L. Haylor, JW Pippin, JY Seo, L Aoudjit, LF Allen, LL Huang, M Peake, M Sabbatini, M Zeisberg, MA Chetram, MH De Borst, N Sakai, P Moreno-Layseca, PM Lorusso, R Ohashi, R Roskoski Jr, S Omori, S Wang, S Wang, SD Oldroyd, SK Jo, SP Davies, T Ishida, T Masaki, T Wada, T Xu, W Bechtel, Y Han   +50 more
core   +29 more sources

Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. [PDF]

Journal of the National Cancer Institute, 2002
BACKGROUND: Urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) play essential roles in tumor invasion and metastasis. High levels of both uPA and PAI-1 are associated with poor prognosis in breast cancer patients ...
M. Look, W. van Putten, M. Duffy, N. Harbeck, I. Christensen, C. Thomssen, R. Kates, F. Spyratos, M. Fernö, S. Eppenberger-Castori, C. Sweep, K. Ulm, J. Peyrat, P. Martin, H. Magdelenat, N. Brünner, C. Duggan, B. Lisboa, P. Bendahl, V. Quillien, A. Daver, G. Ricolleau, M. M. Meijer-van Gelder, P. Manders, W. Fiets, M. Blankenstein, P. Broët, S. Romain, G. Daxenbichler, G. Windbichler, T. Čufer, S. Borstnar, W. Kueng, L. Beex, J. Klijn, N. O’higgins, U. Eppenberger, F. Jänicke, M. Schmitt, J. Foekens   +39 more
semanticscholar   +3 more sources

A Serpin With a Finger in Many PAIs: PAI-1's Central Function in Thromboinflammation and Cardiovascular Disease

Frontiers in Cardiovascular Medicine, 2021
Plasminogen activator inhibitor 1 (PAI-1) is a member of the serine protease inhibitor (serpin) superfamily. PAI-1 is the principal inhibitor of the plasminogen activators, tissue plasminogen activator (tPA), and urokinase-type plasminogen activator (uPA)
G. Morrow, C. Whyte, N. Mutch
semanticscholar   +1 more source

Upaya Meningkatkan Hasil Belajar Siswa Kelas VIII A SMP Negeri 1 Buntulia Pada Mata Pelajaran Pendidikan Agama Islam Melalui Penerapan Model Pembelajaran Kooperatif tipe Think Talk Write

Aksara, 2021
Penelitian ini merupakan Penelitian Tindakan Kelas (PTK) dengan mencoba menerapan salah satu model pembelajaran untuk mengaktifkansiswa dan mengefektifkan proses pembelajaran yaitu pembelajaran kooperatif tipe Think Talk Write.
Warni Diange
doaj   +1 more source

PAI-1 in Diabetes: Pathophysiology and Role as a Therapeutic Target

International Journal of Molecular Sciences, 2021
Hypofibrinolysis is a key abnormality in diabetes and contributes to the adverse vascular outcome in this population. Plasminogen activator inhibitor (PAI)-1 is an important regulator of the fibrinolytic process and levels of this antifibrinolytic ...
Rawan Altalhi, N. Pechlivani, R. Ajjan
semanticscholar   +1 more source

Role of PAI-1 in hepatic steatosis and dyslipidemia

Scientific Reports, 2021
Plasminogen activator inhibitor 1 (PAI-1) is a functional biomarker of the metabolic syndrome. Previous studies have demonstrated that PAI-1 is a mechanistic contributor to several elements of the syndrome, including obesity, hypertension and insulin ...
J. Levine, C. Oleaga, M. Eren, A. Amaral, Meng Shang, E. Lux, S. Khan, Sanjiv J. Shah, Yasuhiro Omura, N. Pamir, Joshua Hay, G. Barish, T. Miyata, H. Tavori, S. Fazio, D. Vaughan   +15 more
semanticscholar   +1 more source

Glomerular endothelial cell senescence drives age‐related kidney disease through PAI‐1

EMBO Molecular Medicine, 2021
The mechanisms underlying the development of glomerular lesions during aging are largely unknown. It has been suggested that senescence might play a role, but the pathophysiological link between senescence and lesion development remains unexplained. Here,
Camille Cohen, Océane Le Goff, F. Soysouvanh, F. Vasseur, Marine Tanou, Clément Nguyen, L. Amrouche, J. Le Guen, Oriana Saltel-Fulero, T. Meunier, T. Nguyen‐Khoa, M. Rabant, D. Nochy, C. Legendre, G. Friedlander, Bennett G. Childs, Darren J. Baker, B. Knebelmann, D. Anglicheau, F. Milliat, F. Terzi   +20 more
semanticscholar   +1 more source

PAI-1 and kidney fibrosis [PDF]

Frontiers in Bioscience, 2009
Substantial evidence demonstrates a link of increased plasminogen activator inhibitor-1 (PAI-1) and glomerulosclerosis and kidney fibrosis, providing a novel therapeutic option for prevention and treatment of chronic kidney diseases. Several mechanisms contributing to increased PAI-1 will be addressed, including classic key profibrotic factors such as ...
Li-Jun, Ma, Agnes B, Fogo
openaire   +2 more sources

Salt-inducible kinases (SIKs) regulate TGFβ-mediated transcriptional and apoptotic responses [PDF]

, 2020
The signalling pathways initiated by members of the transforming growth factor-β (TGFβ) family of cytokines control many metazoan cellular processes, including proliferation and differentiation, epithelial-mesenchymal transition (EMT) and apoptosis. TGFβ
A Rojas-Fernandez, A Woods, AR Ramjaun, AY Hsing, B Bierie, B Ozdamar, B-C Kim, BR Binder, C Allan, CJ David, CS Hill, DB Shackelford, EC Connolly, FA Ran, G Avery-Cooper, G Rena, G Rosti, GD Cuny, GJ Inman, GJ Inman, GM Keating, H Ikushima, J Massagué, J Massagué, J Massaous, J Ozanne, J Song, J Vogt, J Xu, JF Callahan, JL Wrana, JM Lizcano, Joan Massagué, JY Altarejos, K Clark, KA Brown, KJ Livak, LC Spender, LC Spender, M Abe, M Kowanetz, M Tojo, MO Li, MR Keeton, NJ Bright, P Lönn, PH Lin, PK Datta, PM Siegel, RJ Akhurst, RJ Akhurst, S DaCosta Byfield, S Dennler, S Edlund, S Strickson, SA Hawley, T Sonntag, TB Sundberg, Y Drabsch, Y Liu, Y Shi, Y Yang, Y Zhang, Y Zhang   +63 more
core   +2 more sources